Invokana Dosage/Direction for Use

Prior to Initiation of INVOKANA: Assess renal function before initiating INVOKANA and periodically thereafter [see Acute Kidney Injury under Precautions].
In patients with volume depletion not previously treated with canagliflozin, normalize volume status before initiating INVOKANA [see Hypotension, Renal Impairment, Use in Elderly under Precautions].
Recommended Dosage: The recommended starting dose of INVOKANA (canagliflozin) is 100 mg once daily, taken before the first meal of the day. In patients tolerating INVOKANA 100 mg once daily who have an eGFR of 60 mL/min/1.73 m² or greater and require additional glycemic control, the dose can be increased to 300 mg once daily [see Patients with Renal Impairment as follows, Pharmacology: Pharmacokinetics under Actions, and Patient Counselling Information].
Patients with Renal Impairment: The dose of INVOKANA is limited to 100 mg once daily in patients with moderate renal impairment with an eGFR of 45 to less than 60 mL/min/1.73 m².
Initiation of INVOKANA is not recommended in patients with an eGFR less than 45 mL/min/1.73 m².
Use of INVOKANA is not recommended when eGFR is persistently less than 45 mL/min/1.73 m² [see Acute Kidney Injury and Renal Impairment under Precautions].
INVOKANA is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m² [see Contraindications].
Concomitant Use with UDP-Glucuronosyl Transferase (UGT) Enzyme Inducers: If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKANA, consider increasing the dosage to 300 mg once daily in patients currently tolerating INVOKANA 100 mg once daily who have an eGFR of 60 mL/min/1.73 m² or greater and require additional glycemic control [see UGT Enzyme Inducers under Interactions].
Consider another antihyperglycemic agent in patients with an eGFR of 45 to less than 60 mL/min/1.73 m² receiving concurrent therapy with a UGT inducer.